BioPharm International
March 02, 2008
Articles
2008 Supplement
3
Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology.
March 02, 2008
Articles
2008 Supplement
3
An alternative approach to traditional Protein A schemes is comparable in overall efficiency, product recovery, and quality.
March 02, 2008
Articles
2008 Supplement
3
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
March 02, 2008
Articles
2008 Supplement
3
If certain engineering challenges can be addressed, precipitation may prove to be a valuable tool for antibody purification.
March 02, 2008
Articles
2008 Supplement
3
When platform processes are applied to fusion molecules, innovation and flexibility are needed.